RE: Early Stage Cancer Treatment23 Jun 2023 15:09
RNS of 11th August 2021, first patient dosed in AVA6000 trial,
"If the study shows that the pre|CISIONTM technology is effective in reducing systemic toxicity of Doxorubicin in humans, then that would open up an extensive and proprietary pipeline for Avacta of next-generation pre|CISIONTM pro-drug chemotherapies with significant clinical and commercial advantages in a chemotherapy market that is expected to exceed $74 billion by 2027."
so yes, i think they have the bigger picture on their radar.